We are live on ! Find out more
PBE icon

Invesco Biotechnology & Genome ETF
PBE

64 hedge funds and large institutions have $52.9M invested in Invesco Biotechnology & Genome ETF in 2017 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 21 increasing their positions, 16 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

31% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 16

3% less capital invested

Capital invested by funds: $54.4M → $52.9M (-$1.47M)

1.63% less ownership

Funds ownership: 23.27% → 21.64% (-1.6%)

6% less funds holding

Funds holding: 68 → 64 (-4)

33% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 6

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
64
Holders Change
-4
Holders Change %
-5.88%
% of All Funds
1.6%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
4
Increased
21
Reduced
16
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
LTFS
Ladenburg Thalmann Financial Services
Florida
+$639K
2
RJFSA
Raymond James Financial Services Advisors
Florida
+$637K
3
SPIA
Steward Partners Investment Advisory
New York
+$527K
4
MML Investors Services
MML Investors Services
Massachusetts
+$511K
5
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$338K

Top Sellers

Rank Fund Capital Flow
1
Stifel Financial
Stifel Financial
Missouri
-$5.83M
2
Citadel Advisors
Citadel Advisors
Florida
-$1.38M
3
UBS Group
UBS Group
Switzerland
-$954K
4
Bank of America
Bank of America
North Carolina
-$453K
5
HighTower Advisors
HighTower Advisors
Illinois
-$412K
Name Holding Trade Value Shares
Change 		Change in
Stake
RJA
26
Raymond James & Associates
Florida
$543K +$57.5K +1,332 +13%
MML Investors Services
27
MML Investors Services
Massachusetts
$541K +$511K +11,838 New
AG
28
Advisor Group
Arizona
$498K +$2.42K +56 +0.5%
Janney Montgomery Scott
29
Janney Montgomery Scott
Pennsylvania
$451K +$21.3K +493 +5%
FHA
30
Flagship Harbor Advisors
Massachusetts
$373K – – –
GT
31
Glenview Trust
Kentucky
$350K – – –
TAM
32
Trillium Asset Management
Massachusetts
$316K – – –
JIC
33
Joel Isaacson & Co
New York
$307K – – –
Goldman Sachs
34
Goldman Sachs
New York
$297K -$252K -5,832 -47%
BRF
35
B. Riley Financial
California
$279K – – –
WB
36
Webster Bank
Connecticut
$246K -$14.9K -345 -6%
CIC
37
Carnegie Investment Counsel
Ohio
$225K +$86 +2 +0%
VKH
38
Virtu KCG Holdings
New York
$211K -$203K -4,705 -50%
Envestnet Asset Management
39
Envestnet Asset Management
Illinois
$165K +$47.1K +1,091 +43%
Citigroup
40
Citigroup
New York
$141K +$8.72K +202 +7%
IA
41
IFP Advisors
Florida
$95K +$8.85K +205 +11%
Creative Planning
42
Creative Planning
Kansas
$78K +$42.7K +990 +139%
GT
43
Glenmede Trust
Pennsylvania
$66K – – –
JCM
44
Jacobi Capital Management
Pennsylvania
$55K – – –
SEI Investments
45
SEI Investments
Pennsylvania
$43K +$7.81K +181 +24%
LF
46
Lee Financial
Texas
$35K – – –
Manulife (Manufacturers Life Insurance)
47
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$27K +$12.9K +300 +100%
FANJ
48
Financial Architects (New Jersey)
New Jersey
$23K – – –
WA
49
WFG Advisors
Texas
$21K – – –
NFG
50
Next Financial Group
Texas
$21K +$10.8K +250 +125%
1
2
3

PBE Hedge Fund Activity: Q2 2017 in Review

64 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Invesco Biotechnology & Genome ETF (PBE) for Q2 2017, worth a combined $52.9M — down 2.7% from $54.4M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of PBE and 4 opened new positions — a net loss of 2 holders — while 16 trimmed existing stakes and 21 added.

The largest buyer was Ladenburg Thalmann Financial Services, adding an estimated $639K. The largest seller was Stifel Financial, cutting an estimated $5.83M.

  • 64 institutional investors held Invesco Biotechnology & Genome ETF (PBE) as of Q2 2017, down from 68 in Q1 2017.
  • Funds reported $52.9M of Invesco Biotechnology & Genome ETF stock for Q2 2017, down 2.7% quarter-over-quarter.
  • 4 funds opened new Invesco Biotechnology & Genome ETF positions in Q2 2017 and 6 closed out, a net change of -2 holders.
  • The largest Invesco Biotechnology & Genome ETF buyer in Q2 2017 was Ladenburg Thalmann Financial Services, an estimated $639K added.
  • The largest Invesco Biotechnology & Genome ETF seller in Q2 2017 was Stifel Financial, an estimated $5.83M sold.

Based on aggregated 13F filings for Q2 2017.